AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

15.59USD-0.35 (-2.20%)Delayed as of 17 May 2024, 03:07 pm ET

Market Summary

USD15.59-0.35

Delayedas of 17 May 2024, 03:07 pm

-2.20%

AVDL Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

AVDL Stock Price

View Fullscreen

AVDL RSI Chart

AVDL Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-9.77

Price/Sales (Trailing)

27.83

EV/EBITDA

-10.27

Price/Free Cashflow

-11.97

AVDL Price/Sales (Trailing)

AVDL Profitability

EBT Margin

-284.61%

Return on Equity

-200.08%

Return on Assets

-93.41%

Free Cashflow Yield

-8.35%

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

55.0M

Rev. Growth (Yr)

14.0K%

Rev. Growth (Qtr)

40.41%

AVDL Earnings

Earnings (TTM)

-156.8M

Earnings Growth (Yr)

11.18%

Earnings Growth (Qtr)

5.02%

Breaking Down AVDL Revenue

52 Week Range

9.7216.85

(Low)(High)

Last 7 days

0.6%

Last 30 days

-11.9%

Last 90 days

17.4%

Trailing 12 Months

7.6%

How does AVDL drawdown profile look like?

AVDL Financial Health

Current Ratio

2.85

AVDL Investor Care

Shares Dilution (1Y)

25.20%

Diluted EPS (TTM)

-1.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	55.0M	0	0	0
2023	1.6M	2.3M	9.2M	28.1M
2022	0	1.9M	1.9M	0
2021	17.3M	12.3M	7.3M	2.3M
2020	55.0M	47.6M	33.3M	22.3M
2019	86.4M	74.7M	69.1M	59.2M
2018	154.4M	136.6M	116.7M	103.3M
2017	166.2M	175.1M	182.7M	173.6M
2016	176.6M	166.2M	150.9M	149.9M
2015	54.5M	94.0M	133.6M	173.1M
2014	6.9M	9.6M	12.3M	15.0M
2013	6.7M	5.9M	5.0M	4.2M
2012	26.3M	20.1M	13.8M	7.5M
2011	35.6M	34.1M	0	32.6M
2010	0	0	0	37.1M
2009	0	0	0	42.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avadel Pharmaceuticals PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 16, 2024	mchugh thomas s	bought	29,000	14.5	2,000	chief financial officer
Dec 28, 2023	mccamish mark anthony	sold	-1,089,750	14.53	-75,000	-
Aug 14, 2023	mchugh thomas s	bought	28,900	14.45	2,000	chief financial officer
Aug 11, 2023	mccamish mark anthony	sold	-432,614	14.9306	-28,975	-
Aug 10, 2023	divis gregory j	bought	131,997	13.1997	10,000	chief executive officer
Aug 10, 2023	glass geoffrey michael	bought	187,600	13.4	14,000	-
May 18, 2023	ende eric j	bought	181,100	13.9308	13,000	-
May 09, 2023	palczuk linda	bought	36,900	14.76	2,500	-
Dec 23, 2022	palczuk linda	bought	14,405	7.2025	2,000	-
Nov 29, 2022	mchugh thomas s	bought	39,000	7.8	5,000	chief financial officer

Which funds bought or sold AVDL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Cetera Advisor Networks LLC	added	78.15	195,517	368,388	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	786	27,722,000	30,610,000	0.01%
May 15, 2024	Cetera Advisors LLC	added	8.91	361,225	1,554,170	0.01%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-2,182,740	-	-%
May 15, 2024	ALGERT GLOBAL LLC	sold off	-100	-218,000	-	-%
May 15, 2024	Polar Asset Management Partners Inc.	added	17.14	337,093	1,177,230	0.02%
May 15, 2024	MPM BIOIMPACT LLC	added	31.00	5,324,100	14,713,700	2.37%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	5,438,580	5,438,580	0.04%
May 15, 2024	Lion Point Capital, LP	added	3.12	263,825	1,393,420	0.78%
May 15, 2024	Cubist Systematic Strategies, LLC	added	1,722	2,715,870	2,846,440	0.02%

Are Funds Buying or Selling AVDL?

Are funds buying AVDL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVDL

No. of Funds

Unveiling Avadel Pharmaceuticals PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	9.99%	9,196,186	SC 13G/A
Feb 13, 2024	polar capital holdings plc	7.51%	6,751,782	SC 13G
Feb 13, 2024	janus henderson group plc	12.4%	11,125,330	SC 13G/A
Feb 13, 2024	gendell jeffrey l	3.94%	3,539,782	SC 13G/A
Feb 12, 2024	kotler kevin	4.1%	3,716,242	SC 13G/A
Aug 10, 2023	janus henderson group plc	12.3%	9,443,642	SC 13G
Mar 09, 2023	kotler kevin	5.1%	3,122,100	SC 13G
Feb 14, 2023	gendell jeffrey l	5.33%	3,294,817	SC 13G/A
Feb 14, 2023	rtw investments, lp	9.3%	5,741,939	SC 13G/A
Feb 14, 2023	vivo opportunity, llc	3.6%	2,251,663	SC 13G/A

Recent SEC filings of Avadel Pharmaceuticals PLC

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	424B5	Prospectus Filed
May 08, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
May 03, 2024	3	Insider Trading
Apr 26, 2024	10-K/A	Annual Report
Apr 15, 2024	8-A12B	8-A12B
Apr 15, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Avadel Pharmaceuticals PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	371.3B	85.6B	6.80%	-2.97%	9.65	4.33	5.68%	202.39%
MRK	331.6B	61.4B	4.69%	14.08%	143.8	5.4	6.11%	-82.30%
AMGN	168.9B	29.5B	18.50%	39.89%	44.87	5.72	12.76%	-52.47%
PFE	163.9B	57.8B	12.61%	-21.28%	130.78	2.84	76.51%	-86.81%
GILD	84.6B	27.4B	0.85%	-13.87%	174.55	3.08	1.51%	-91.32%
TEVA	18.5B	16.0B	24.52%	100.49%	-37.33	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	2.99%	-21.03%	9.53	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	0.47%	-8.40%	-532.89	0.9	-0.06%	94.55%
BHC	2.6B	9.0B	-19.11%	-5.35%	-5.7	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.47%	-0.56%	13.51	3.09	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	16.39%	-11.62%	-4.68	2.22	24.65%	80.36%
TXMD	24.2M	1.3M	10.53%	-49.88%	-3.27	18.6	-98.14%	-104.71%
ACRX	19.7M	89.6M	13.73%	58.80%	-1.39	0.19	287.27%	-129.41%
AGRX	2.6M	21.5M	2.56%	-90.89%	-0.34	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Avadel Pharmaceuticals PLC News

Latest updates

Avadel Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	40.4%	27,178,000	19,356,500	7,014,000	1,496,000	193,000	448,000	192,000	812,000	489,000	432,000	216,000	-	-	10,091,000	12,243,000	10,995,000	14,229,000	17,554,000	16,437,000	20,920,000	19,826,000
Gross Profit	36.8%	25,656,000	18,760,000	6,897,000	1,460,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	42,007,000	51,001,000	28,298,000	16,960,000	29,937,000	23,136,000	25,663,000	21,936,000	14,811,000	14,260,000	13,697,000	-30,178,000	18,740,000	18,342,000	18,376,000	22,005,000	24,604,000	96,341,000	33,921,000
Operating Expenses	-	51,691,000	-	-	-	28,298,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	17.7%	48,623,000	41,301,000	39,158,000	46,778,000	24,468,000	14,096,000	21,804,000	21,026,000	21,283,000	15,174,000	11,012,000	8,974,000	8,423,000	7,095,000	7,913,000	7,663,000	5,316,000	6,758,000	10,446,000	23,200,000	24,829,000
R&D Expenses	30.1%	3,068,000	2,359,000	2,849,000	4,223,000	3,830,000	2,933,000	4,541,000	2,110,000	4,380,000	6,762,000	3,852,000	5,286,000	5,569,000	4,057,000	5,530,000	7,757,000	7,539,000	10,292,000	7,329,000	6,086,000	11,402,000
EBITDA Margin	50.2%	-2.65	-5.31	-15.97	-55.22	-58.75	-49.65	-54.67	-35.16	-9.61	-4.76	0.14	-	-	-	-	-	-	-	-	-	-
Interest Expenses	10.1%	2,592,000	2,354,000	1,978,000	2,295,000	3,259,000	3,564,000	3,506,000	4,154,000	1,929,000	1,930,000	1,929,000	3,308,000	3,259,000	3,237,000	3,190,000	3,190,000	3,125,000	3,106,000	3,062,000	3,045,000	3,000,000
Income Taxes	193.0%	93,000	-100,000	89,000	90,000	-580,000	70,000	30,193,000	-4,343,000	-5,101,000	-3,765,000	-2,607,000	-2,852,000	-5,040,000	5,292,000	-9,510,000	-8,997,000	2,234,000	1,781,000	-374,000	-14,533,000	-691,000
Earnings Before Taxes	5.7%	-27,249,000	-28,886,000	-36,185,000	-64,342,000	-31,364,000	-20,076,000	-33,251,000	-26,644,000	-27,103,000	-23,346,000	-16,052,000	-14,130,000	-16,743,000	36,166,000	-10,375,000	-11,736,000	-6,630,000	-6,824,000	-13,392,000	-78,392,000	-16,462,000
EBT Margin	50.3%	-2.85	-5.73	-17.40	-61.46	-68.12	-57.04	-61.17	-39.75	-10.98	-5.70	-0.62	-	-	-	-	-	-	-	-	-	-
Net Income	5.0%	-27,342,000	-28,786,000	-36,274,000	-64,432,000	-30,784,000	-20,146,000	-63,444,000	-22,301,000	-22,002,000	-19,581,000	-13,445,000	-11,278,000	-11,703,000	30,874,000	-865,000	-2,739,000	-8,864,000	-8,605,000	-13,018,000	-63,859,000	-15,771,000
Net Income Margin	50.1%	-2.85	-5.71	-17.37	-61.32	-86.22	-68.17	-69.70	-33.00	-9.03	-4.54	-0.32	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.0%	-29,704,000	-28,029,000	-38,226,000	-32,023,000	-30,233,000	-7,519,000	-14,090,000	-22,506,000	-21,238,000	-10,153,000	-23,439,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.9%	168	165	203	201	141	133	146	158	221	247	264	283	293	312	328	341	208	151	156	166	174
Current Assets	1.4%	136	134	172	171	109	101	113	126	161	192	206	231	242	263	282	277	131	82.00	89.00	97.00	102
Cash Equivalents	14.8%	36.00	31.00	52.00	50.00	83.00	74.00	61.00	54.00	61.00	51.00	58.00	67.00	59.00	72.00	83.00	102	74.00	10.00	13.00	17.00	10.00
Inventory	14.9%	12.00	10.00	5.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	2.00	3.00	4.00
Net PPE	-10.1%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	2.00
Goodwill	0%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	18.00	18.00	18.00	18.00	18.00
Liabilities	16.3%	90.00	77.00	93.00	58.00	179	154	158	161	166	169	165	164	156	149	156	159	176	181	183	183	183
Current Liabilities	29.7%	48.00	37.00	54.00	52.00	79.00	56.00	42.00	46.00	44.00	21.00	18.00	16.00	9.00	15.00	23.00	27.00	32.00	36.00	32.00	34.00	31.00
Long Term Debt	-	-	-	-	-	93.00	92.00	110	108	117	142	142	142	141	128	127	125	123	122	120	119	117
LT Debt, Current	-	-	-	21.00	21.00	21.00	38.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
LT Debt, Non Current	-	-	-	-	-	93.00	92.00	110	108	117	142	142	142	141	128	127	125	123	122	120	119	117
Shareholder's Equity	-10.7%	78.00	88.00	110	143	-38.17	-21.14	-	-	55.00	78.00	99.00	119	137	162	171	182	32.00	-	-	-	-
Retained Earnings	-3.7%	-772	-745	-716	-680	-616	-585	-557	-537	-474	-447	-425	-403	-383	-384	-372	-361	-392	-391	-388	-379	-371
Additional Paid-In Capital	2.2%	874	855	852	849	603	590	573	560	554	549	547	544	542	567	565	615	497	434	434	434	434
Shares Outstanding	7.0%	96.00	90.00	89.00	89.00	64.00	63.00	59.00	59.00	59.00	59.00	59.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,459	-	-	-	142	-	-	-	390	-	-	-	467	-	-	-	98.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-6.0%	-29,704	-28,029	-38,226	-32,023	-30,233	-15,366	-6,803	-14,090	-34,045	-22,506	-21,238	-10,153	-23,413	-19,125	-10,192	-7,781	-11,636	-8,253	-7,419	-1,447	-21,206
Share Based Compensation	53.2%	5,389	3,518	3,127	7,644	1,522	1,927	1,923	658	2,505	2,784	2,359	2,001	1,728	1,294	194	769	742	342	-229	55.00	351
Cashflow From Investing	-23.4%	21,387	27,928	9,821	-92,908	5,066	22,875	2,524	12,048	42,251	15,320	12,294	18,124	11,191	7,241	-9,300	-80,888	13,226	5,170	3,217	8,946	21,390
Cashflow From Financing	162.5%	13,190	-21,111	30,460	91,544	34,442	6,622	10,715	-4,803	2,009	-	114	-	149	183	-16.00	117,306	62,210	-41.00	-41.00	-37.00	92.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVDL Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (27,342)	$ (30,784)
Other comprehensive (loss) income, net of tax:
Foreign currency translation (loss) income	(236)	175
Net other comprehensive (loss) income, net of income tax expense of $0 and $0, respectively	(353)	140
Total other comprehensive (loss) income, net of tax	(589)	315
Total comprehensive loss	$ (27,931)	$ (30,469)

AVDL Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,794	$ 31,167
Marketable securities	52,995	73,944
Accounts receivable, net	22,692	12,103
Inventories	11,928	10,380
Research and development tax credit receivable	1,293	1,322
Prepaid expenses and other current assets	11,333	5,286
Total current assets	136,035	134,202
Property and equipment, net	526	585
Operating lease right-of-use assets	2,374	2,591
Goodwill	16,836	16,836
Research and development tax credit receivable	360	332
Other non-current assets	11,768	10,152
Total assets	167,899	164,698
Current liabilities:
Current portion of operating lease liability	953	934
Accounts payable	18,961	11,433
Accrued expenses	27,642	24,227
Other current liabilities	252	261
Total current liabilities	47,808	36,855
Long-term operating lease liability	1,449	1,690
Royalty financing obligation	34,333	32,760
Other non-current liabilities	5,925	5,654
Total liabilities	89,515	76,959
Shareholders’ equity:
Preferred shares, nominal value of $0.01 per share; $50,000 shares authorized; zero issued and outstanding at March 31, 2024 and $5,194 issued and outstanding at December 31, 2023	0	52
Ordinary shares, nominal value of $0.01 per share; $500,000 shares authorized; $96,097 issued and outstanding at March 31, 2024 and $89,825 issued and outstanding at December 31, 2023	960	898
Additional paid-in capital	874,018	855,452
Accumulated deficit	(772,838)	(745,496)
Accumulated other comprehensive loss	(23,756)	(23,167)
Total shareholders’ equity	78,384	87,739
Total liabilities and shareholders’ equity	$ 167,899	$ 164,698

About Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

CEO	Mr. Gregory J. Divis Jr.
WEBSITE	avadel.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	41

Avadel Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Avadel Pharmaceuticals PLC? What does AVDL stand for in stocks?

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avadel Pharmaceuticals PLC (AVDL)?

As of Thu May 16 2024, market cap of Avadel Pharmaceuticals PLC is 1.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers. The fair value of Avadel Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avadel Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVDL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avadel Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether AVDL is over valued or under valued. Whether Avadel Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Avadel Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVDL.

What is Avadel Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, AVDL's PE ratio (Price to Earnings) is -9.77 and Price to Sales (PS) ratio is 27.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avadel Pharmaceuticals PLC's stock?

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.045 (multiply by 100 for percentage) rate of return.